Recent years have seen a huge surge of interest in oligonucleotide therapeutics, fueled by major advances in our understanding of how to make such molecules stable, selective, and efficient as drug modalities. The field is now diverse in terms of therapeutic areas being addressed, biological processes being manipulated and delivery technologies employed. In this webinar, …Read More >

WuXi Discovery Services supports all of your research needs, including target discovery, in vitro and in vivo pharmacology, translational research and clinical biomarker testing, to enable drug discovery for your target compound for pain. Full-scale molecular characterizations from gene/protein expression in vitro functional assays with validation of GPCR, Kinase and ion channel targets Selectivity profiling …Read More >

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond

Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low nanomolar biochemical and single-digit micromolar cellular potencies. Surprisingly the replacement of a phenyl with a pyridyl moiety in the chemical structure revealed a new binding mode for the inhibitors with subtle conformational change of the …Read More >

Lung cancer is the leading cause of cancer-related death worldwide.  Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with poor prognosis and disabling symptoms. However, few therapies have been approved for the treatment …Read More >

The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are established by inoculating mouse cancer cell lines into immunocompetent mice with the same genetic background. The host mice have complete immune activity and show histocompatibility with homograft tumor tissues, which can maximize the simulation of …Read More >

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >